cagrisema semaglutide Novo Nordisk to explore weight-loss potential in new trial CagriSema Shows 22.7% Weight Loss

In June 2021, the FDA approved its use for chronic weight management in adults who are overweight or obese A 2022 study finding once patients go off the medication the average weight gain rebound is about 2/3 of the total weight lost

While tirzepatide has been investigated in type 1 diabetes contexts, its GLP-1 and GIP receptor agonism affects pancreatic function in ways that may interact unpredictably with pancreatic autoimmune processes

Cooper EH, Forbes MA

Your dietitian will work with you to ensure adequate protein and nutrient intake despite potentially reduced appetite, and may adjust your supplementation regimen accordingly